Skip to main content

Table 1 Patient characteristics

From: 3-weekly or weekly cisplatin concurrently with radiotherapy for patients with squamous cell carcinoma of the head and neck – a multicentre, retrospective analysis

Baseline characteristic 3-weekly
(n = 127)
Weekly
(n = 187)
Total
(n = 314)
p-value
Centre < 0,0011
- USB 124 (97,6%) 0 (0%) 124 (39,5%)
- KSW 3 (2,4%) 58 (32%) 61 (19,4%)
- USZ 0 (0%) 129 (69%) 129 (41,1%)
Age at diagnosis, mean (SD) 60.4 (8.1) 59.9 (8.7) 60.1 (8.5) 0.5582
Gender 0.2731
- Male 102 (80.3%) 139 (74.3%) 241 (76.8%)
- Female 25 (19.7%) 48 (25.7%) 73 (23.2%)
Tumor localisation 0.1561
- Oropharynx 57 (45.2%) 102 (54.8%) 159 (51%)
- Oral cavity 30 (23.8%) 27 (14.5%) 57 (18.3%)
- Hypopharynx 21 (16.7%) 27 (14.5%) 48 (15.4%)
- Larynx 10 (7.9%) 21 (11.3%) 31 (9.9%)
- CUP 5 (4.0%) 8 (4.3%) 13 (4.2%)
- Nasopharynx 3 (2.4%) 1 (0.5%) 4 (1.3%)
Smoking History 0.0871
- Smoker 105 (92.9%) 155(85.6%) 260 (88.4%)
- Non smoker 8 (7.1%) 26 (14.4%) 34 (11.6%)
HPV Status 0.0931
-Positive 21 (16.5%) 34 (18.2%) 55 (17.5%)
- Negative 32 (25.2%) 29 (15.5%) 61 (19.4%)
- Unknown 74 (58.3%) 124 (66.3%) 198 (63.1%)
T Stage 0.0811
- T0 0 1 (0.6%) 1 (0.3%)
- T1 14 (11.7%) 29 (16.2%) 43 (14.4%)
- T2 36 (30.0%) 74 (41.3%) 110 (36.8%)
- T3 31 (25.8%) 35 (19.6%) 66 (22.1%)
- T4 39 (32.5%) 40 (22.3%) 79 (26.4%)
N Stage 0.6271
- N0 24 (19.0%) 43 (23.0%) 67 (21.4%)
- N1 13 (10.3%) 25 (13.4%) 38 (12.1%)
- N2 83 (65.9%) 112 (59.9%) 195 (62.3%)
- N3 6 (4.8%) 7 (3.7%) 13 (4.2%)
M Stage 0,4823
- M0 115 (90.5%) 160 (85.5%) 275 (87.5%)
- M1 5 (3.9%) 3 (1.6%) 8 (2.5%)
Advanced Disease (> = T2 & > = N2) 0,0341
- Yes 77 (64,2%) 99 (51.1%) 169 (56.3%)
- No 43 (35,8%) 88 (48,9%) 131 (43,7%)
Type of CRT 0.1471
- Definitive 78 (61.4%) 126 (67.3%) 204 (64.9%)
- Adjuvant 49 (38.6%) 61 (32.7%) 110 (35.1%)
  1. SD Standard deviation, 1Chi-Square test; 2t-test; 3Fisher’s exact test